Results of a large real-world cohort study including more than 3300 patients confirm that ibrutinib is an effective salvage treatment for relapsed/refractory chronic lymphocytic leukemia (R/R...
Final results of the EVIdeNCE study strongly support ibrutinib (Imbruvica; AbbVie/Pharmacyclics) as a valuable treatment option for patients with chronic lymphocytic leukemia (CLL). The EVIdeNCE data,...